Advances in Medicinal Chemistry, Volume 4

Maryanoff, B.E.; Reitz, A.B.

In stock
Regular price 47.500 KD inc. VAT
License
Table of contents
  • Cover
  • CONTENTSv
  • LIST OF CONTRIBUTORSvii
  • PREFACEix
  • CHAPTER 1. NOVEL PEPTIDE MIMETIC BUILDING BLOCKS AND STRATEGIES FOR EFFICIENT LEAD FINDING1
  • CHAPTER 2. RECENT ADVANCES IN THE MEDICINAL CHEMISTRY OF TAXOID ANTICANCER AGENTS69
  • CHAPTER 3. SYNTHESIS AND STRUCTURE–ACTIVITY RELATIONSHIPS OF PEROXIDIC ANTIMALARIALS BASED ON ARTE125
  • CHAPTER 4. DESIGN OF COMPOUND LIBRARIES FOR DETECTING AND PURSUING NOVEL SMALL MOLECULE LEADS219
  • CHAPTER 5. A THEORETICAL MODEL OF THE HUMAN THROMBIN RECEPTOR (PAR-1), THE FIRST KNOWN PROTEASE-ACTI245
  • CHAPTER 6. FARNESYL TRANSFERASE INHIBITORS: DESIGN OF A NEW CLASS OF CANCER CHEMOTHERAPEUTIC AGENTS273
  • INDEX315
Book details
  • Vendor Elsevier S & T
  • SKU 9780762300648
  • ISBN-13 9780080526379
  • Author Maryanoff, B.E.; Reitz, A.B.
  • Category Science
  • Subject Organic

Do you have questions about this book?

Ask an expert!

Volume 4 of Advances in Medicinal Chemistry is comprised of six chapters on a wide range of topics in medicinal chemistry, including molecular modeling, structure-based drug design, organic synthesis, peptide conformational analysis, biological assessment, structure-activity correlation, and lead optimization. Chapter 1 presents an account about amino acid-based peptide mimetics corresponding to b-turn, loop, helical motifs in proteins as a probe of ligand-receptor and ligand-enzyme molecular interactions. Chapter 2 addresses new facets of the medicinal chemistry of the important anticancer drug Taxol® (paclitaxel). Chapter 3 relates an account of the search for new drugs for the treatment of malaria based on the natural product artemisinin. Chapter 4 applies computational chemistry to the evaluation of compound libraries for biological testing. Chapter 5 describes the construction of a 3-dimensional molecular model of the human thrombin receptor, the first protease-activated G-protein coupled receptor (PAR-1), as a means to explore the intermolecular contacts involved in agonist peptide recognition. Finally, Chapter 6 describes the research conducted at Merck on inhibitors of farnesyl transferase as a potential treatment for human cancers.